摘要
目的评价沙美特罗替卡松联合孟鲁司特治疗儿童哮喘的疗效。方法采用计算机检索和手工检索相结合的方法搜索PubMed、Cochrane Library、EMbase、中国期刊全文数据库、中国生物医学文献数据库、维普中文科技期刊数据库、万方医学数据库，时间为从建库至2013年3月。收集沙美特罗替卡松联合孟鲁司特和单用沙美特罗替卡松治疗儿童哮喘的随机对照试验（RCT），对符合纳入标准的研究采用RevMan 5.1软件进行Meta分析。比较沙美特罗替卡松联合孟鲁司特与单用沙美特罗替卡松的疗效。结果共纳入11篇文献，包括410例沙美特罗替卡松联合孟鲁司特治疗患者和378例单用沙美特罗替卡松治疗患者。Meta分析显示，2组患者治疗后最大峰流量差异有统计学意义［加权均数差（WMD）=6.53，95%置信区间（CI）：2.71-10.36，P＜0.01］；治疗后第1秒钟用力呼气容积差异有统计学意义（WMD=7.28，95%CI：3.30-11.26，P＜0.01）；哮喘症状评分差异有统计学意义（WMD=-0.25，95%CI：-0.34--0.17，P＜0.01）；临床控制率差异有统计学意义[比值比（OR）= 1.76，95%CI：1.12-2.75，P=0.01]；有效率差异有统计学意义（OR= 4.32，95%CI：1.63-11.45，P＜0.01）。结论孟鲁司特联合沙美特罗替卡松治疗小儿支气管哮喘在疗效方面优于单用沙美特罗替卡松。
ObjectiveTo assess the efficacy of salmeterol fluticasone combined with montelukast in the treatment of asthma in children. MethodsDatabase such as PubMed, Cochrane Library, EMbase, China knowledge Resource Integrated Database, CBMdisc and Chinese Journal Literature Database were searched. ResultsEleven literatures were reviewed including 410 cases receiving salmeterol fluticasone combined with montelukast and 378 cases receiving salmeterol fluticasone alone. Meta analysis revealed that peak expiratory flow [WMD=6.53,95%CI（2.71,10.36）,P〈0.01], forced expiratory volume in the first second [WMD=7.28,95%CI（3.30,11.26）,P〈0.01], symptom score [WMD=-0.25,95%CI（-0.34,-0.17）,P〈0.01], clinical control rate [OR=1.76,95%CI（1.12,2.75）,P=0.01] and effective rate [OR=4.32,95%CI（1.63,11.45）,P〈0.01] had statistical differences. ConclusionThe efficacy of salmeterol fluticasone combined with montelukast is superior to salmeterol fluticasone alone in the treatment of asthma in children.
出处
《中国医药》
2015年第2期172-176,共5页
China Medicine
